Narula N, Wong ECL, Dulai PS, Marshall JK, et al. Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naive Crohn's Disease. Am J Gastroenterol 2024 Jan 18. doi: 10.14309/ajg.0000000000002654.
PMID: 38235763